Key positive factors include a clear strategic pivot toward a business model—diagnostics—that can, at least in principle, generate revenue more quickly than drug development. Management has demonstrated the ability to substantially reduce operating losses and cash burn, indicating willingness to make difficult decisions. The in‑licensed test portfolio targets real clinical needs with large addressable markets, and prior access to capital suggests that the company has historically been able to secure investor support when needed.

The central concerns are the severely weakened balance sheet, ongoing negative cash flow, and the absence of any revenue track record. Negative equity, thin cash reserves, and rising short‑term debt all point to elevated solvency and dilution risk. The strategic reboot into diagnostics introduces execution risk in unfamiliar commercial territory, with strong incumbent competitors and meaningful regulatory and reimbursement hurdles. Any delays in commercialization or difficulties raising fresh capital could quickly strain the company’s ability to continue as a going concern.

Looking ahead, Hepion’s prospects hinge on whether it can rapidly transition from a cash‑burning, pre‑revenue biotech into a functioning diagnostics business with growing sales. If the company can secure sufficient funding, obtain needed regulatory clearances, and leverage its partnerships to drive adoption in Europe and eventually the United States, its financial profile could gradually improve from today’s stressed state. However, the current data paint a picture of a high‑uncertainty, high‑execution‑risk story, where both operational success and continued access to capital are critical and far from guaranteed.